Canaccord downgraded Verona Pharma (VRNA) to Hold from Buy with a price target of $107, up from $106, after the company entered into an agreement under which Merck (MRK) will acquire it for $107 per American depository share, or $10B.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Verona Pharma downgraded to Hold from Buy at Jefferies
- Video: Verona Pharma jumps after agreeing to be acquired by Merck for $10B
- Morning Movers: Starbucks climbs following reports of interest in China business
- Verona Pharma Stock (VRNA) Soars 20% on $10B Merck Deal
- Verona Pharma Acquired by Merck for $10 Billion